Status:

COMPLETED

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

Lead Sponsor:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborating Sponsors:

Eisai Inc.

Conditions:

Gastroesophageal Reflux

Eligibility:

All Genders

1-11 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to assess the effectiveness and safety of rabeprazole sodium, an inhibitor of gastric acid secretion of the protein pump inhibitor (PPI) class, compared with placebo in th...

Detailed Description

Rabeprazole sodium belongs to the class of drugs known as proton pump inhibitors, which suppress gastric acid secretion. The drug is approved in the United States for the treatment of adults with GERD...

Eligibility Criteria

Inclusion

  • Diagnosis of suspected GERD, symptomatic GERD, or endoscopically or histologically proven GERD, based on frequent vomiting or regurgitation, with at least 1 of the following: a) poor weight gain, or b) irritability, excessive crying or disturbed sleep that both the parent(s) and the doctor consider abnormal (but not due to colic)
  • or c) refusal to eat even if hungry or arching of the back during meals
  • weight 2.5 kg to 15.0 kg
  • I-GERQ-R score \>16
  • Have only 1 caregiver in addition to the parent(s)

Exclusion

  • History of confirmed acute life-threatening events due to GERD
  • Known narrowing of the opening from the stomach to the small intestines
  • Confirmed diagnosis of cow's milk allergy
  • Have taken PPIs or H2-blockers (a class of drugs that inhibit stomach acid production) or any of several drugs that affect the normal movement of the digestive tract (caffeine, theophylline, antacids, erythromycin, and others) within 3 days before entering the study
  • Have blood or urine test results that are well above or below the normal range for the infant

Key Trial Info

Start Date :

November 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2011

Estimated Enrollment :

344 Patients enrolled

Trial Details

Trial ID

NCT00992589

Start Date

November 1 2009

End Date

November 1 2011

Last Update

May 22 2013

Active Locations (81)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 21 (81 locations)

1

Birmingham, Alabama, United States

2

Columbiana, Alabama, United States

3

Dothan, Alabama, United States

4

Huntsville, Alabama, United States